Epstein-Barr virus DNA and latent gene products in Hodgkin's disease and non-Hodgkin's lymphomas (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Epstein-Barr virus DNA and latent gene products in Hodgkin's disease and non-Hodgkin's lymphomas (Meeting abstract).

Molecular Biology of Hematopoiesis, 8th Symposium. July 9-13, 1993, Basel, Switzerland, p. 55, 1993.. Unique Identifier : AIDSLINE ICDB/95699338
Herbst H; Steinbrecher E; Dallenbach F; Niedobitek G; Young LS; Muller-Lantzsch N; Stein H; Inst. of Pathology, Klinikum Steglitz, Free Univ. Berlin, Germany

Abstract: In recent years, techniques, probes and reagents became available to reliably visualize EBV-infected cells, to assess EBV gene expression, and to characterize the clonal composition of EBV genomes in human tissues. Application of these techniques to lymphoproliferative lesions revealed (1) an association of EBV with various mono- and oligoclonal lymphoproliferations ranging from benign to overtly malignant lymphomas, and (2) three characteristic patterns of EBV gene expression among EBV-associated lymphoproliferations, ranging from a minimal to the full spectrum of EBV latent gene products. In view of the established immortalizing and transforming properties of EBV, the findings support the concept of an etiologic role of EBV for certain B- or T-cell lymphomas such as Hodgkin's disease, anaplastic large cell lymphoma, and lymphomas arising in immunocompromised individuals. Because proportions of the EBV infected cells in many of these cases express the transforming protein LMP-1 (latent membrane protein), the virus may influence the proliferative properties as well as the morphology and phenotype of the neoplastic cells. The expression of viral neo-antigens known to represent targets for cytotoxic T-cells reflects either specific defects in the immune response or global immunodeficiencies as seen in HIV-associated disease.

Keywords: Cell Transformation, Viral DNA, Viral/*GENETICS Gene Expression Regulation, Viral Herpesvirus 4, Human/*GENETICS Hodgkin's Disease/*GENETICS Human Immunocompromised Host Lymphoma, Non-Hodgkin's/*GENETICS Oncogene Proteins, Viral/GENETICS Viral Matrix Proteins/GENETICS Viral Proteins/*GENETICS ABSTRACT
950228
M9521053

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .